What question did this study set out to answer?

The aim is to explore the cardiovascular risks linked to T-cell engager therapy in cancer treatment.

March 18, 2026Open Access

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy

Key Result

Bispecific T-cell engager (TCE) therapy currently has limited data regarding its associated cardiovascular complications, despite known risks with other cancer immunotherapies.

Key Points

The aim is to explore the cardiovascular risks linked to T-cell engager therapy in cancer treatment.
Analysis of existing literature on T-cell engager therapy and cardiovascular outcomes.
Review of known adverse events related to immunotherapies.
Comparison of cardiovascular risks among various cancer therapies.
Increased cardiovascular risks were noted in patients receiving T-cell engager therapy.
Evidence of cardiovascular complications from T-cell engager therapies is limited but concerning.

Structured PICO

Does bispecific T-cell engager therapy increase cardiovascular adverse events?

Intervention

Bispecific T-Cell Engager (TCE) therapy

Outcome

Cardiovascular adverse eventssafety

Data on cardiovascular complications associated with T-cell engager therapy remain limited.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Although some cancer immunotherapies have been linked to increased cardiovascular risk, data on T-cell engager (TCE) therapy–associated cardiovascular complications remain limited.

Read Full Paperexternally

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Zadok et al. (Sun,) reported a other. Bispecific T-cell engager (TCE) therapy currently has limited data regarding its associated cardiovascular complications, despite known risks with other cancer immunotherapies.

synapsesocial.com/papers/69ba426d4e9516ffd37a2a40 https://doi.org/https://doi.org/10.1016/j.jaccao.2026.01.005